No Data
No Data
Piper Sandler Maintains Overweight on Cardiff Oncology, Raises Price Target to $10
Cardiff Oncology Analyst Ratings
Piper Sandler Maintains Cardiff Oncology(CRDF.US) With Buy Rating, Raises Target Price to $10
TD Cowen Maintains Cardiff Oncology(CRDF.US) With Buy Rating
Cardiff Oncology Director Gary Pace Buys $940,199 in Stock
CRDF Stock Soars on Robust Efficacy Data From Colorectal Cancer Study
EZ_money OP : I'm holding onto to this one
EZ_money OP : it's owned by vanguard, BlackRock, and State Street capital...the biggest 3 in the market